logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11230699 B1

PDFFull Text
Date of Patent:
Jan. 25, 2022

Filed:

Jan. 28, 2020

Chimeric antigen receptor-modified nk-92 cells targeting egfr super-family receptors

Applicant:

Nantkwest, Inc., Culver City, CA (US);

Inventors:

John H. Lee, Culver City, CA (US);

Laurent H. Boissel, Culver City, CA (US);

Hans G. Klingemann, Culver City, CA (US);

Assignee:

ImmunityBio, Inc., Culver City, CA (US);

Attorneys:

Martin Fessenmaier

Umberg Zipser LLP

Primary Examiner:

Quang Nguyen

Int. Cl.
CPC ...
A61K 48/00 (2006.01); C07H 21/04 (2006.01); C12N 5/0783 (2010.01); C07K 16/32 (2006.01); C07K 14/735 (2006.01); C07K 14/55 (2006.01); C07K 14/54 (2006.01); C07K 14/71 (2006.01); A61K 35/17 (2015.01); A61P 35/00 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01); C12N 15/00 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0646 (2013.01); A61K 35/17 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 14/5434 (2013.01); C07K 14/5443 (2013.01); C07K 14/55 (2013.01); C07K 14/70535 (2013.01); C07K 14/71 (2013.01); C07K 16/2863 (2013.01); C07K 16/32 (2013.01); C07K 2317/24 (2013.01); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01);
Abstract

Provided are genetically modified NK cells expressing a chimeric antigen receptor targeting an EGFR superfamily receptor. The CAR can comprise an intracellular domain of FcεRIγ and further recombinant proteins expressed by the genetically modified NK cells are CD16, autocrine growth stimulating cytokines, and optionally one of IL-12, a TGF-beta trap, or a homing receptor. Also described are methods for treating a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer, comprising administering to the patient the genetically modified NK cells.

Find Patent Forward Citations

Loading…